CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Apremilastdrug
Likely dose
Apremilast 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01393158
NCT01393158Phase 2Completed
CompareCT.gov

A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults

Oregon Health and Science University·interventional·Posted Jul 13, 2011·Updated Jan 14, 2020

In Brief

A Phase 2 clinical trial evaluating Apremilast for Atopic Dermatitis. Completed, enrolled 16 participants.

Detailed Summary

The purpose of this study is to obtain preliminary data regarding the safety and tolerability of apremilast in AD to support the design of larger controlled studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
Countries--
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 13, 2011
Enrollment StartMay 1, 2009
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.0 years ago

Interventions

Apremilastdrug

20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.